2019 International Congress Archives - Page 29 of 217

1:45pm-3:15pm: Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.

H. Bouchaoui, L. Mahoney-Sanchez, A. Jonneaux, F. Gouel, M. Dutheil, JC. Devedjian, G. Garçon, D. Devos (Lille, France)

Neuropharmacology · Les Muses Terrace, Level 3

1:45pm-3:15pm: Fine-mapping of SNCA variants in REM sleep behavior disorder identifies distinct associations

L. Krohn, R. Wu, J. Ruskey, S. Laurent, L. Philstrom, I. Arnulf, M. Hu, Y. Dauvilliers, B. Hogl, A. Stefani, E. Holzknecht, C. Monaca, A. Beatriz, G. Plazzi, E. Antelmi, L. Ferini-Strambi, A. Heidbreder, V. Cochen, B. Mollenhauer, K. Sonka, M. Figorilli, F. Dijkstra, M. Viaene, W. Oertel, J. Gagnon, M. Nalls, C. Blauwendraat, A. Singleton, A. Desautels, J. Montplaisir, O. Ross, B. Boeve, N. Dupre, E. Fon, R. Postuma, G. Rouleau, Z. Gan-Or (Montreal, QC, Canada)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit

JB. Paredes, J. Poles, V. Hristova, S. Madrona, S. Argos, P. Torre, JL. Moreno, I. Moreno, JC. Castrillo, A. Canovas (Madrid, Spain)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: First-In-Human Study of LY3154207, a Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

K. Biglan, K. Svensson, W. Kielbasa (Indianapolis, IN, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

A. Jain, S. Jain (Sagar, India)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Four-Week Trunk-Specific Exercise Program decreases Forward Trunk Flexion in Parkinson’s disease: a single- blinded, randomized controlled trial

M. Gandolfi, M. Tinazzi, F. Magrinelli, G. Buselli, E. Dimitrova, N. Polo, P. Manganotti, A. Fasano, N. Smania, C. Geroin (Verona, Italy)

Physical and Occupational Therapy · Les Muses Terrace, Level 3

1:45pm-3:15pm: Fragile X Gray Zone Alleles in Men are associated with Parkinsonism

D. Hall, S. Nag, E. Berry-Kravis, A. Ali, B. Ouyang, Y. Liu, A. Buchman, D. Bennett (Chicago, IL, USA)

Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3

1:45pm-3:15pm: Fragile X syndrome presenting with levodopa unresponsive parkinsonism

J. Mayer, J. Panicker, S. Alusi (Liverpool, United Kingdom)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Frequency of neuropsychiatric symptoms in non-demented early and late-onset Parkinson’s disease patients

A. Seubert-Ravelo, MG. Yáñez-Téllez, G. Neri-Nani, X. Ortiz-Jiménez, C. Guerra-Galicia (Estado de México, Mexico)

Psychiatric Manifestations · Les Muses Terrace, Level 3

1:45pm-3:15pm: Functional exam findings in Lewy Body Disease

J. Nguyen, K. Papesh (Las Vegas, NV, USA)

Functional (Psychogenic) Movement Disorders · Les Muses Terrace, Level 3